Phase Ia trial of ACH 3102 in healthy subjects

Trial Profile

Phase Ia trial of ACH 3102 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Odalasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 23 Apr 2013 Status changed from recruiting to completed, based on information in Achillion Pharmaceuticals media releases.
    • 27 Sep 2012 To date, 42 volunteers have received single dose ACH 3102 and 32 volunteers have received multiple-dose treatment, according to an Achillion Pharmaceuticals media release.
    • 07 Aug 2012 Preliminary results published in an Achillion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top